This document summarizes the results of a study that compared the change in HbA1c levels over time for patients taking rosiglitazone (ROSI), metformin (MET), or glyburide (GLY) to treat type 2 diabetes. It found that the annualized slope, or rate of change in HbA1c, was lowest for ROSI at 0.07%, higher for MET at 0.14%, and highest for GLY at 0.24%. The difference in HbA1c between ROSI and MET was 0.13% and between ROSI and GLY was 0.42%. It also notes that multiple studies have shown that thiazolidinediones like ROSI can prevent progression

1. 6.0 6.4 6.8 7.2 7.6 8.0 ADOPT, NEJM 355: 2427-43, 2006 TIME-RELATED CHANGE IN HbA 1c Difference in HbA1c (%) ROSI vs MET= 0.13%, p<0.002 ROSI vs GLY =0.42%, p<0.001 Glyburide Metformin Rosiglitazone Annualized Slope ROSI = 0.07 MET = 0.14* GLY = 0.24* Glycated Hemoglobin (%) 5 4 3 2 1 0 YEARS Number 4012 3308 2991 2583 2197 822